arrow
D

Dan Cacsire Castillo-Tong

Medical University of Vienna
H指数:40
被引数:4,399

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models

Lurbinectedin在PARP抑制剂耐药的高级别浆液性卵巢癌中的治疗效果:基于患者来源的细胞系和类器官模型

2025-09-210
OAAI
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication
2024-02-091
OA
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2022-11-051
PRE
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2022-09-095
OAAI
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer
2019-09-0116
OAAI
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study)
2018-06-2917
OAAI
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2017-07-0129
OAAI
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer

AID/APOBEC-网络重建识别与卵巢癌生存相关的途径

2016-08-1615
OAAI